Results 261 to 270 of about 382,920 (355)

Altered cytokine and chemokine profiles in multiple myeloma and its precursor disease

open access: green, 2014
Adriana Zingone   +18 more
openalex   +2 more sources

Distribution of adult T‐cell leukaemia/lymphoma subtypes and survival outcomes across geographical regions: An international retrospective cohort study

open access: yesBritish Journal of Haematology, EarlyView.
Summary Although adult T‐cell leukaemia/lymphoma (ATL) has a higher burden in certain world regions, outcomes have not been directly compared across regions. We conducted a multicentre cohort study comparing the distribution of ATL subtypes and overall survival (OS) across 1090 adults (≥18 years) diagnosed with ATL during 2000–2023 in Japan (n = 366 ...
Bryan Valcarcel   +31 more
wiley   +1 more source

Long-term outcomes and treatment patterns in Waldenström macroglobulinemia patients who discontinue Bruton tyrosine kinase inhibitor (BTKi) therapy

open access: yesBlood Cancer Journal
Karan L. Chohan   +13 more
doaj   +1 more source

Triplet or Quadruplet Regimen Utilization and Overall Survival in Patients Diagnosed With Multiple Myeloma Between 2017 and 2023. [PDF]

open access: yesEJHaem
Wesley ER   +10 more
europepmc   +1 more source

Prospective implementation of the HCT frailty scale in adults with lymphoproliferative syndromes candidates for autologous haematopoietic stem cell transplantation: Results from a multicentre GETH‐TC study

open access: yesBritish Journal of Haematology, EarlyView.
Summary This prospective study evaluated the incidence and dynamics of frailty in 156 adults with lymphoproliferative syndromes undergoing autologous haematopoietic stem cell transplantation (HSCT). Frailty was assessed using the haematopoietic cell transplantation (HCT) frailty scale in patients from 15 Spanish institutions at initial consultation ...
Javier Cornago   +30 more
wiley   +1 more source

Sustained disease remission after a limited duration of bispecific antibody therapy in patients with multiple myeloma. [PDF]

open access: yesHemasphere
Vega G   +18 more
europepmc   +1 more source

Targeting Siglec–sialic acid checkpoint to reverse immune dysfunction mediated by plasmacytoid dendritic cells in myeloma

open access: yesBlood Advances
Arghya Ray   +9 more
doaj   +1 more source

Oxidative Stress in Multiple Myeloma: Pathogenic Mechanisms, Biomarkers, and Redox-Targeted Therapeutic Strategies. [PDF]

open access: yesInt J Mol Sci
Bilski R   +7 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy